HomeOwner SearchCategory Search
Visit USCONovel Extracellular Signal-Regulated Kinase (ERK) Targeted Inhibitors Effects on Apoptotic Signaling A Potential Cancer Therapy
Text Registration
Copyright Title
Novel Extracellular Signal-Regulated Kinase (ERK) Targeted Inhibitors Effects on Apoptotic Signaling A Potential Cancer Therapy
Status
Published
on 29 Sept 2011
Year of Creation
2011
Copyright Claimant
Sarice R. Boston
Registration Number
TX0006732034
on 29 Sept 2011Copyright Summary
The U.S. Copyright record (Registration Number: TX0006732034) dated 29 Sept 2011, pertains to an electronic file (eService) titled "Novel Extracellular Signal-Regulated Kinase (ERK) Targeted Inhibitors Effects on Apoptotic Signaling A Potential Cancer Therapy" created in 2011. The copyright holder is Sarice R. Boston, known for their creative contributions in text registration. For any inquiries concerning this copyrighted material, kindly reach out to Sarice R. Boston.
Application Details
Registration Number
TX0006732034
Registration Date
9/29/2011
Year of Creation
2011
Agency Marc Code
DLC-CO
Record Status
New
Physical Description
Computer text data
Notes
Rights Note: Rights and permissions info. on CORDS appl. in CO
Local Copyright Note: Electronic registration
Statements
Author Statement: entire text: Sarice R. Boston
© 2024 reserved by Trademarkia
Show terms & conditions
Disclaimer: The information contained in this website is provided for informational purposes only, and should not be construed as legal advice. Although LegalForce RAPC Worldwide P.C., dba Trademarkia P.C., is a law firm (the “Firm”), your use of this website does not establish an attorney-client relationship with the Firm. Such a relationship can only be established after the Firm decides that it is willing and able to accept the engagement after a conflict check and after a written retainer agreement is agreed upon between you and the Firm. Your use of this website is also subject to our Terms of Use and Privacy Policy. ** The entry level subscription is a bundled price which requires a minimum of two billing cycles, or 6 months.